NASDAQ:TCDA - Tricida Stock Price, Forecast & News

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

3 Wall Street analysts have issued 12-month target prices for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they expect Tricida's stock price to reach $51.50 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

Headlines about TCDA stock have trended somewhat negative on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Tricida.

Tricida saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 4,340,000 shares, an increase of 8.0% from the November 28th total of 4,020,000 shares. Based on an average trading volume of 303,500 shares, the days-to-cover ratio is presently 14.3 days. Currently, 12.2% of the shares of the stock are sold short. View Tricida's Current Options Chain.

Some companies that are related to Tricida include The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), GW Pharmaceuticals PLC- (GWPH), Ocular Therapeutix (OCUL), AT&T (T), Affimed (AFMD) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was purchased by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $33.28.

Tricida has a market capitalization of $1.65 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]